CN115209905A - 用于提高耐药性呼吸道细菌的易感性并降低其抗生素耐药性的外源性一氧化氮 - Google Patents

用于提高耐药性呼吸道细菌的易感性并降低其抗生素耐药性的外源性一氧化氮 Download PDF

Info

Publication number
CN115209905A
CN115209905A CN202180018358.5A CN202180018358A CN115209905A CN 115209905 A CN115209905 A CN 115209905A CN 202180018358 A CN202180018358 A CN 202180018358A CN 115209905 A CN115209905 A CN 115209905A
Authority
CN
China
Prior art keywords
4mic
hours
cos
antibiotic
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018358.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·舍恩菲施
K·R·罗拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN115209905A publication Critical patent/CN115209905A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
CN202180018358.5A 2020-02-14 2021-02-11 用于提高耐药性呼吸道细菌的易感性并降低其抗生素耐药性的外源性一氧化氮 Pending CN115209905A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062976738P 2020-02-14 2020-02-14
US62/976,738 2020-02-14
US202063125865P 2020-12-15 2020-12-15
US63/125,865 2020-12-15
PCT/US2021/017711 WO2021163367A1 (en) 2020-02-14 2021-02-11 Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria

Publications (1)

Publication Number Publication Date
CN115209905A true CN115209905A (zh) 2022-10-18

Family

ID=77292649

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018358.5A Pending CN115209905A (zh) 2020-02-14 2021-02-11 用于提高耐药性呼吸道细菌的易感性并降低其抗生素耐药性的外源性一氧化氮

Country Status (6)

Country Link
US (1) US20230082968A1 (enExample)
EP (1) EP4103199A4 (enExample)
JP (1) JP2023513750A (enExample)
CN (1) CN115209905A (enExample)
AU (1) AU2021218708B2 (enExample)
WO (1) WO2021163367A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114191559A (zh) * 2021-11-04 2022-03-18 陕西省微生物研究所 一种no增强抗生素抗菌敏感性的方法及应用
CN119789870A (zh) * 2022-06-08 2025-04-08 诺欧生物有限责任公司 含有一氧化氮释放化合物的多组分药物组合物和试剂盒及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200716741A (en) * 2005-05-24 2007-05-01 Environmental Biotechnology Crc Pty Ltd Methods and compositions for regulating biofilm development
WO2009049208A1 (en) * 2007-10-12 2009-04-16 The University Of North Carolina At Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
CN106986952B (zh) * 2012-08-17 2020-03-10 北卡罗来纳大学查珀尔希尔分校 水溶性的释放一氧化氮的聚葡糖胺和其用途

Also Published As

Publication number Publication date
EP4103199A4 (en) 2024-04-03
JP2023513750A (ja) 2023-04-03
AU2021218708A1 (en) 2022-09-29
US20230082968A1 (en) 2023-03-16
WO2021163367A1 (en) 2021-08-19
EP4103199A1 (en) 2022-12-21
AU2021218708B2 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
Kumar et al. Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens
Hawas et al. Combination therapies for biofilm inhibition and eradication: a comparative review of laboratory and preclinical studies
Si et al. A glycosylated cationic block poly (β‐peptide) reverses intrinsic antibiotic resistance in all ESKAPE gram‐negative bacteria
Zemke et al. Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells
Hetrick et al. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles
Mohamed et al. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate
Upadya et al. Role of efflux pump inhibitors on the antibiofilm efficacy of calcium hydroxide, chitosan nanoparticles, and light-activated disinfection
Jia et al. Antibacterial effect of S-Porphin sodium photodynamic therapy on Staphylococcus aureus and multiple drug resistance Staphylococcus aureus
Ni et al. An inhalable gallium-polyphenol nanoparticle blocks bacterial electron transport chain and signal transduction for anti-biofilm therapy
BRPI0920042B1 (pt) Uso de um composto na preparação de um medicamento para o tratamento de uma infecção de biofilme bacteriano
AU2021218708B2 (en) Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria
Sun et al. Iodine/soluble starch cryogel: an iodine-based antiseptic with instant water-solubility, improved stability, and potent bactericidal activity
Heydari et al. The synergic activity of eucalyptus leaf oil and silver nanoparticles against some pathogenic bacteria
Urquhart et al. Antimicrobial activity of water-soluble tetra-cationic porphyrins on Pseudomonas aeruginosa
Grayton et al. Biofilm dispersal, reduced viscoelasticity, and antibiotic sensitization via nitric oxide-releasing biopolymers
Maklakova et al. Role of biofilm formation in the drop of bacterial resistance to antibiotics after animal therapy with silver nanoparticles
Huang et al. Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
CA3171167A1 (en) Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria
US11998560B2 (en) Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against multidrug and extensively drug-resistant Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates
Guo et al. Copper (ii) complexes with porphyrins for photodynamic elimination of drug-resistant pathogens
da Rosa Pinheiro et al. Antimicrobial photodynamic in vitro inactivation of Enterococcus spp. and Staphylococcus spp. strains using tetra-cationic platinum (II) porphyrins
Özkanca et al. Prevention of antibiotic resistance created by experimental evolutionary microbiology in Staphylococcus aureus and Escherichia coli with herbal substances
ES2902456T3 (es) Composiciones farmacéuticas que comprenden agentes antibacterianos
Wang et al. A novel ROS switcher potentiates the type-I photodynamic effect of sodium zinc chlorophyllin against Pseudomonas aeruginosa in diabetic wounds
Bhowmik et al. Successfully treating biofilms of extensively drug resistant Klebsiella pneumoniae isolates from hospital patients with N-Acetyl Cysteine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination